Steven Klein

Steven brings over 20 years of business development experience in industry and non-profit organisations across a variety of fields, including oncology, vaccines, and CNS-related indications.

Steven previously held several business development leadership roles, where he successfully negotiated numerous strategic transactions and managed alliances with a wide range of biopharmaceutical companies, including BMS, Ipsen, Abbvie, Merck, Pfizer, Roche, Nippon Shinyaku, Grunenthal, AstraZeneca, Domain Therapeutics, and Medigene.

Steven holds a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.